Open Access

Posttranslational modifications of α-tubulin in alzheimer disease

  • Fan Zhang1, 2,
  • Bo Su3,
  • Chunyu Wang1, 4,
  • Sandra L. Siedlak1,
  • Siddhartha Mondragon-Rodriguez5,
  • Hyoung-gon Lee1,
  • Xinglong Wang1,
  • George Perry6 and
  • Xiongwei Zhu1, 7Email author
Contributed equally
Translational Neurodegeneration20154:9

DOI: 10.1186/s40035-015-0030-4

Received: 14 January 2015

Accepted: 30 April 2015

Published: 15 May 2015

Abstract

Background

In Alzheimer disease (AD), hyperphosphorylation of tau proteins results in microtubule destabilization and cytoskeletal abnormalities. Our prior ultra-morphometric studies documented a clear reduction in microtubules in pyramidal neurons in AD compared to controls, however, this reduction did not coincide with the presence of paired helical filaments. The latter suggests the presence of compensatory mechanism(s) that stabilize microtubule dynamics despite the loss of tau binding and stabilization. Microtubules are composed of tubulin dimers which are subject to posttranslational modifications that affect the stability and function of microtubules.

Methods

In this study, we performed a detailed analysis on changes in the posttranslational modifications in tubulin in postmortem human brain tissues from AD patients and age-matched controls by immunoblot and immunocytochemistry.

Results

Consistent with our previous study, we found decreased levels of α-tubulin in AD brain. Levels of tubulin with various posttranslational modifications such as polyglutamylation, tyrosination, and detyrosination were also proportionally reduced in AD brain, but, interestingly, there was an increase in the proportion of the acetylated α-tubulin in the remaining α-tubulin. Tubulin distribution was changed from predominantly in the processes to be more accumulated in the cell body. The number of processes containing polyglutamylated tubulin was well preserved in AD neurons. While there was a cell autonomous detrimental effect of NFTs on tubulin, this is likely a gradual and slow process, and there was no selective loss of acetylated or polyglutamylated tubulin in NFT-bearing neurons.

Conclusions

Overall, we suggest that the specific changes in tubulin modification in AD brain likely represent a compensatory response.

Keywords

Acetylation Alzheimer disease Polyglutamylation Tau Tubulin

Background

Alzheimer disease (AD), as the most common neurodegenerative disease, is characterized by the pathological markers such as intracellular neurofibrillary tangles (NFTs) and extracellular senile plaques. NFTs are mainly composed of a highly phosphorylated form of the microtubule associated protein tau, and senile plaques are primarily composed of amyloid-β. Physiologically, tau regulates microtubule stability by binding to microtubules. Phosphorylation and dephosphorylation of tau at specific sites such as Ser262 or Thr231 regulates its binding ability to microtubules [1, 2]. In AD patients, hyperphosphorylated tau proteins have low tubulin-binding activity and form paired helical filaments which are believed to lead to microtubule destabilization and cytoskeletal abnormalities [3].

Our previous ultra-morphometric study demonstrated that microtubules are significantly reduced in number and length in AD neurons, however, their loss does not correspond with the formation of paired helical filaments [4]. In fact, abundant microtubules were often seen in close juxtaposition to paired helical filaments, suggesting that microtubule deficit is independent of tau filament formation [4]. Even though the overall function of microtubules and cellular actions dependent on microtubules including axonal transport are likely compromised [58], neurons continue to be functionally integrated and survive despite increased levels of phosphorylated tau proteins and deposited filaments [9, 10]. This suggests the presence of mechanism(s) compensating for the loss of tau binding/stabilizing activity affecting microtubules in these neurons.

Microtubules are composed of tubulin heterodimers made of α- and β-tubulin. The C-terminal tail of α-tubulin is subject to posttranslational modifications such as detyrosination, acetylation, and polyglutamylation, which affects the function and stability of microtubules [11, 12]. We hypothesize that compensatory changes in posttranslational modification of tubulin could alleviate deficits induced by microtubule destabilization/reduction in susceptible neurons in AD brain. To begin to test this hypothesis, we performed a detailed immunoblot and immunocytochemical analysis to investigate various posttranslational modifications to tubulin in the brain tissue from AD and control patients.

Methods

Human tissues and Immunocytochemistry

Human brain tissue samples were obtained postmortem from patients with histopathologically-confirmed AD (n = 3) (see Table 1) and non-AD controls (n = 4. Except for the lack of NFTs, the young control case (C1) demonstrated similar staining pattern as other controls cases for all the antibodies used). Tissue was fixed in methacarn (methanol:chloroform:acetic acid in a 6:3:1 ratio) immersion for 24 h at 4 °C. Tissue was subsequently dehydrated through graded ethanol and xylene solutions, embedded in paraffin, and sectioned at 6 μm. Following hydration, sequential sections were immunostained by the peroxidase-antiperoxidase procedure with DAB as chromogen [13] using mouse monoclonal antibodies against α-tubulin (Epitomics, Burlingame, CA, USA), acetylated tubulin (Sigma, St. Louis, MO, USA, product#T6793), tyrosinated tubulin (Sigma, Product# T9028), detyrosinated tubulin (Chemicon, cata#MAB5566) and polyglutamylated tubulin (Sigma, Product#T9822). Sections were also double stained for NFT using a rabbit antibody against tau protein and the alkaline phosphatase anti alkaline phosphatase method and developed with Fast Blue.
Table 1

Details of Alzheimer disease and control cases used in the immunocytochemical studies

Case

Neuropathological Diagnosis

Gender

Age

# NFT/mm2 CA1

AD 1

Alzheimer disease

F

76

55.4

AD 2

Alzheimer disease, severe

F

77

81.6

AD 3

Alzheimer disease

F

88

29.9

C 1

No pathological diagnosis

M

62

0

C 2

Infarcts

F

69

0.8

C 3

No pathological diagnosis

F

74

8.1

C 4

No pathological diagnosis

M

81

7.8

Double-label immunofluorescence images

Following rehydration brain tissue sections were blocked with 10 % normal goat serum in phosphate-buffered saline for 1 h, then incubated with primary antibody pSer396 (Biosource, Camarillo, CA, USA. 1:200) and acetylated tubulin overnight at 4 °C. Following three washes, the sections were incubated with 488/564-conjugated secondary antibody (Invitrogen, Grand Island, NY, USA) (1:500) for 1 h at 37 °C in the dark. Tissues were rinsed three times with phosphate-buffered saline and mounted with antifade medium (Southern Biotech, Birmingham, AL, USA). All fluorescence images were captured with a Zeiss LSM 510 inverted fluorescence microscope or a Zeiss LSM 510 inverted laser-scanning confocal fluorescence microscope.

Western blotting

Samples of frozen gray matter of hippocampus of AD (n = 9, age 78.3 ± 1.7, postmortem interval of 6 ± 1.6 h) and control cases (n = 8, ages 74.1 ± 4.7, postmortem interval of 7.4 ± 2 h, there was no significant difference in the age and postmortem intervals between AD and control groups) were homogenized in 10 x volumes of lysis buffer (Cell Signaling, Danvers, MA, USA) and centrifuged for 10 min at 16,000 x g. Protein concentration of the supernatants was determined by the bicinchoninic acid assay method (Pierce, Rockford, IL, USA). Western blot was performed to examine α-tubulin, acetylated tubulin, tyrosine tubulin, polyglutamylated tubulin, detyrosinated tubulin, and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) (Millipore, Bedford, MA, USA) levels in samples.

Blots were scanned at high resolution and the immunoreactive bands were quantitated with Quantity One software (Bio-rad, Hercules, CA, USA). The quantification results (means ± SEM) were analyzed used the Student's t-test to determine the significance (p < 0.05).

Results

Levels of post-translational modifications of tubulin in the hippocampus, including acetylated tubulin, tyrosinated tubulin, detyrosinated tubulin, and polyglutamylated tubulin along with total expression levels of α-tubulin, were determined by western blot (Fig. 1a). Expression levels of GAPDH were also determined by western blot as an internal loading control. Quantitative analysis, normalized to the levels of GAPDH (Fig. 1b), revealed that levels of total α-tubulin were significantly reduced by approximately 65 % in the brains from AD patients compared to age-matched control brains. Similarly, levels of acetylated tubulin, polyglutamylated tubulin, tyrosinated tubulin, and detyrosinated tubulin were also significantly reduced in AD brain (Fig. 1b). The significant reduction of tyrosinated tubulin, detryosinated tubulin, and polygluatmylated tubulin in the AD brains was proportional to the reduction of the total α-tubulin since there was no difference between AD and control brains when the levels of these modified tubulins were normalized to total α-tubulin (Fig. 1c). However, when normalized to total α-tubulin, the ratio of acetylated tubulin was significantly increased by approximately 31 % in AD compared to controls (Fig. 1c), suggesting that acetylated tubulin is more resistant to degradation in AD.
Fig. 1

Immunoblot analysis of tubulins in AD brain. (a) Representative immunoblot analysis of tubulin expression and post-translational modifications in brain homogenates from hippocampal tissues from AD and age-matched control patients. GAPDH was used as the internal loading control. (b) The quantification results, normalized to GAPDH levels, confirmed a significant decrease in α-tubulin, acetylated tubulin, polyGlu-tubulin, tyrosinated tubulin, and detyr-tubulin levels. (c) The quantification results, normalized to α-tubulin levels, demonstrated an increase in acetylated tubulin (Ace TUB). Data are means ± SEM. * indicates significant difference between AD and control with p < 0.05

We next examined the localization of the various tubulin populations in AD and control hippocampal sections by immunocytochemistry. At the light level, all cases examined showed clear and specific immunostaining for each of the monoclonal tubulin modification antibodies. The same region of the CA1 was shown for each antibody in a control case with no NFT and in an AD case with blue-stained NFT (Fig. 2a). All the tubulin antibodies stained many long axonal processes plus finer processes between axons and occasional neuronal cell bodies in the control cases. The AD cases appeared to have fewer axons stained but the cell bodies were more apparent. Further, qualitatively, there appeared to be fewer of the finer processes immunostained in the AD cases, such that only the thicker processes were stained.
Fig. 2

Immunocytochemical analysis of tubulins in AD brain. Representative images of the CA1 region demonstrate specific staining of the tubulin antibodies for neuron cell bodies and axonal processes in both control and AD cases (a). Tubulin antibodies are stained brown and NFT, using tau antibody, are stained blue. Qualitatively it appears that there are fewer processes stained in the AD cases and that only the thicker processes are retained (A). Quantification found there are significantly fewer processes stained for alpha, acetylated, tyrosinated, and detyrosinated tubulin in AD cases (b). When normalized to α-tubulin levels, an increase in stable glutamylated tubulin was found in AD cases (c). *p < 0.05. Scale bar = 50 μm

Quantification of the immunostained axonal processes in the CA1 region by each of these tubulin antibodies found there was less tubulin in the AD cases. The number of processes stained was significantly lower in the CA1 for the α-tubulin, and the acetylated, tyrosinated, and detyrosinated modifications while there was only a trend of reduction for the polyglutamylated tubulin that did not reach significance (Fig. 2b). Within each case, it was possible to directly compare how each modification was maintained in the CA1 neuronal population relative to α-tubulin. No significant difference was found in the proportion of processes with acetylated, tyrosinated, or detyrosinated tubulin between AD and control, but the proportion of processes with polyglutamylated tubulin was significantly increased in AD (Fig. 2c).

To discern the potential effects of NFTs on tubulin expression and modifications, double staining methods were employed. For each modification, other than the few ghost NFTs, all the NFT-bearing neurons contained various levels of tubulins, either in the axons or also in the cell body. Among all cases examined, the majority of NFT-bearing neurons counted in the entire CA1 region (on average around 78 %) were lacking any axonal process stained for tubulin, yet maintained some tubulin immunoreactivity in the cell body (arrowheads in Fig. 3a, left panels), however, for each modification, there were still some NFT-bearing neurons (on average around 22 %) with long axonal processes stained for tubulins (Fig. 3a, right panels, arrows). The pathological tau (stained blue) was restricted to the cell body and only a short distance down the axon. Measuring the length of the cell body and stained axonal processes revealed significantly shorter neurons/processes when NFT were present, compared to all surrounding tubulin-positive cells lacking NFT in all AD cases and the control cases with NFT (Fig. 3b,c). Yet, no difference was noted in these normal neurons or NFT-bearing neurons between the AD and control cases (Fig. 3c), suggesting the neuronal tubulin morphology changes are a reflection of NFT pathology and not disease state.
Fig. 3

The relationship between neuronal tubulin levels and NFTs. Most neurons with NFT (mean 78 %) did not demonstrate axonal processes stained for tubulins (a, arrowheads left panels). However, some neurons with NFT (blue), had tubulin staining in the cell body and axonal process (A, arrows). Every tubulin modification was retained in the axonal process in some NFT-bearing neurons (A, right panels). Scale bars = 50 μm. Measuring the lengths of the cell bodies and axonal processes in the NFT and normal surrounding neurons in the CA1 region found the NFTs were indeed significantly shorter (b) in all AD cases and one control case. Taken together, the NFT in both AD and control cases, were significantly shorter when compared to the normal neuron population (c), yet no difference in length was found when comparing AD and control NFT, or AD and control normal neurons, suggesting the loss of axonal process length is a result of NFT formation and not disease. *p < 0.001, **p < 0.05

It was previously reported that NFT-bearing neurons contain less acetylated tubulin [14]. However, such a pattern was not confirmed in our study as various levels of acetylated tubulin were observed in NFT-bearing neurons similar to that of the NFT-free neurons. NFT-bearing neurons with comparable levels of acetylated tubulin as compared to those neighboring neurons without NFTs were frequently observed. This staining pattern was noted in using light level immunohistochemistry and was also confirmed with double label fluorescent microscopy (Fig. 4). Similarly, various levels of polyglutamylated tubulin were also observed in NFT-bearing neurons with many NFT-bearing neurons demonstrating comparable levels of polyglutamylated tubulin as compared to neighboring neurons without NFT, again seen using both staining methodologies (Fig. 5).
Fig. 4

NFT-bearing neurons do not necessarily contain less acetylated tubulin. (a) Confocal microscopy demonstrated that in AD hippocampal tissues, those neurons containing neurofibrillary pathology (red, arrowheads) display levels of acetylated tubulin (green) comparable to those without NFT (arrows). (b) The same pattern was found using light level microscopy with acetylated tubulin stained brown, and phospho-tau stained blue

Fig. 5

NFT-bearing neurons do not necessarily contain less polyglutamylated tubulin. (a) Levels of polyglutamylated tubulin (red) are similar in both normal and NFT-bearing neurons stained with phosphorylated tau (green). Blue: DAPI. (b) The same pattern was found using light level microscopy with glutamylated tubulin stained brown, and phospho-tau stained blue

Discussion

One of the key features associated with AD is hyperphosphorylation of tau protein which reduces its binding affinity to microtubules, thus resulting in instability and dysfunction of microtubule and related axonal transport [3]. However, despite the fact that tangle bearing neurons lose substantial amounts of structurally normal microtubules [6, 15], prior studies demonstrated that neurons survive decades in the presence of tangles [16]. This suggests that possible compensatory mechanisms may support a sufficiently efficient microtubule network and axonal transport and/or a gradual loss of essential functions of microtubule network. In the current study, we made several interesting observations: 1) there were significantly reduced levels of α-tubulin along with proportional reduction in the absolute levels of polyglutamylated, tyrosinated, and detyrosinated tubulin in the AD brain; 2) despite the significant reduction in the absolute level, acetylated tubulin was proportionally increased in the remaining α-tubulin in the AD brain; 3) α-tubulin and modified tubulins were more accumulated in the cell bodies and thicker processes in AD neurons compared to predominant distribution in both thicker axonal processes and finer branches in neurons in the control brain; 4) the number of processes decorated by polyglutamylated tubulin was not significantly decreased in AD brain. In fact, it was proportionally and significantly increased in AD when normalized with that of α-tubulin; 5) the majority of NFT-bearing neurons lack tubulin-decorated axons, but there were still significant number of NFT-bearing neurons with such long axons; and 6) there was no correlation between the presence of NFTs and the immunoreactivity of acetylated tubulin or polyglutamylated tubulin in the neurons in AD brain.

The finding of decreased total expression levels of α-tubulin and the decreased number of α-tubulin positive axonal processes in the AD cases in the present work is consistent with our previous ultrastructural analysis study, which shows that both number and total length of microtubules were significantly and selectively reduced in pyramidal neurons from AD in comparison to control cases [4]. Indeed, other deficiencies related to abnormal microtubules such as deficits in fast axonal transport, dystrophic neurites, and abnormal mitochondrial distribution [6, 1720] are also reported in AD brains, suggesting that decreased α-tubulin expression could contribute to such deficits and to the pathogenesis of AD. It is not clear what the functional significance of increased levels of α-tubulin in the cell body and the proximal end of the axon processes, but it explains the observation of close juxtaposition of abundant microtubules to paired helical filaments [4] since NFTs are normally accumulated in these regions.

One interesting finding in our study is that despite the reduction in the absolute levels of acetylated tubulin in AD brain, when normalized to reduced levels of α-tubulin, there is increased proportion of acetylated tubulin in the remaining α-tubulin in AD. Acetylation occurs after microtubule assembly at the ε-amine of lysine 40 localized on the inside of the microtubule polymers, which is preserved in α-tubulin but not β-tubulin [21, 22]. Acetylated α-tubulin is present in stable, long-lived microtubules with slow dynamics [23]. One interpretation is that microtubules containing acetylated α-tubulin are better preserved than other microtubules in AD brains. This may be due to its distinct localization in mature neurons as it is enriched in the proximal site of the axon and dendrites [24]. Indeed, our results indicated that the thicker axonal processes are better preserved while those finer processes likely representing branches are lost in AD neurons.

The function of tubulin acetylation remains to be fully understood. Although the early studies indicated that acetylation itself does not confer stability unto microtubules, it was difficult to distinguish whether the acetylation dictated microtubule stability or whether stabilized microtubules became more extensively modified [25]. Nevertheless, tubulin acetylation helps in stability by promoting salt bridge formation between adjacent protofilaments [26]. In the presence of tau protein, acetylated tubulin makes microtubule resistant to the action of severing protein katanin [27]. Functional studies demonstrated that acetylation of α-tubulin is essential for the association of motor proteins (i.e., dynein and kinesin) with microtubules and enhances kinesin-based transport in cells [2830]. However, these observations were not confirmed in purified cell free system [31, 32], suggesting that tubulin acetylation may indirectly impact intracellular transport requiring additional factors in cells. We suspect that the increased proportion of acetylated tubulin in AD may represent an adaptive change in compensation for the loss of microtubules and their associated deficits in axonal transport along microtubules. Such a notion is supported by the finding that acetylated tubulin can be stress-induced in the hippocampus [33] and tubulin hyperacetylation appears to be a common response to several cellular stresses by modulating the binding and function of signaling factors essential for cell survival [3436]. In this regard, it is of interest to note that inhibition of histone deacetylase 6 (HDAC6), the major tubulin deacetylase, increased the amount of acetylated tubulin and concomitantly stimulated vesicular transport of brain-derived neurotrophic factor in neuronal cell lines and compensates for the transport deficit in Huntington’s disease models [37]. Similarly, a recent study found HDAC6 null mutation rescued tau-induced microtubule defects in drosophila through increased tubulin acetylation [38]. In fact, HDAC6 inhibition alleviates cognitive deficits in transgenic mouse models of AD [39, 40] and also improves memory in a mouse model of tau deposits [41].

Another interesting finding of this study is the better preserved number of processes decorated by polyglutamylated tubulin recognized by the B3 polyglutamylated tubulin antibody which demonstrated significantly increased ratio in the remaining processes positive for α-tubulin. Tubulin polyglutamylation is abundant in neurons which involves the addition of one to six glutamyl units to γ-carboxyl group of glutamate at the C-terminal tail domain of both α- and β-tubulin [4244]. Because we focused on modifications to α-tubulin, we chose to use the B3 monoclonal polyglutamylation antibody which preferentially recognizes polyglutamylated α-tubulin [45]. However, since this antibody recognizes only polyglutamylated α-tubulin containing side chains with ≥2 glutamate residues [45, 46], it must be emphasized that it does not provide information of all forms glutamylated α-tubulin due to the obvious lack of detection for monoglutamylated form. The function of tubulin polyglutamylation remains poorly characterized partly due to the complex tubulin polyglutamylation patterns [47], but it is believed that tubulin glutamylation is involved in fine-tuning a range of microtubule functions by regulating the binding to microtubule of various microtubule-associated proteins including tau, MAP1A, 1B and 2 and motor proteins including both kinesins and dyneins [4851]. For example, kinesin-1 motility is increased by tubulin polyglutamylation [52] and in vivo study suggested polyglutamylation of α-tubulin as a molecular traffic sign for correct targeting of KIF1 kinesin required for continuous synaptic transmission [51]. Therefore, such an increased ratio of polyglutamylated tubulin in the remaining tubulin-positive processes may help to preserve essential functions of microtubules such as axonal transport. The recent finding of tubulin polyglutamylation stimulated spastin-mediated microtubule severing suggest that tubulin polyglutamylation could act as a signal to control microtubule mass and stability within a cell [53]. However such a signal is likely context specific and the outcomes are mediated by spatially restricted tubulin interactors of diverse nature within the same cell since another study demonstrated that hyperelongation of glutamyl side chains stabilized cytoplasmic microtubules and destabilized axonemal microtubules [54]. It is possible that the increased polyglutamylated tubulin in the soma along with its reduction in the neuronal process observed in human AD brain may represent an adaptation process helping to stabilize the microtubule structures so as to compensate for the overall loss of microtubules.

Comparing the length of tubulin-positive axons in neurons with or without NFTs in AD and control brain revealed that NFT-free neurons demonstrated similar length between AD and control, suggesting there is no specific effects of disease state. We found that NFT formation caused reduced length of axonal processes decorated by α-tubulin and its modified forms in NFT-bearing neurons in both AD and control patients, indicating a specific detrimental and cell autonomous effect of tau pathology on microtubule. This is likely a gradual and chronic process because significant numbers of NFT-bearing neurons still display long axons similar to that of NFT-free neurons. Prior studies demonstrated a selective loss of acetylated tubulin in the NFT-bearing neurons [14]. We did not find such a pattern. Many NFT-bearing neurons with long axons demonstrated similar levels of acetylated tubulin comparable to neighboring NFT-free neurons, while in those NFT-bearing neurons without long axons, acetylated tubulin was detected in the cell body. Similar observations were made for polyglutamylated tubulin as well. These data suggest that the detrimental effects of tau pathology on microtubule are unlikely mediated through the selective reduction of specific posttranslational modifications of tubulin.

Notes

Abbreviations

AD: 

Alzheimer disease

GAPDH: 

Glyceraldehyde 3-phosphate dehydrogenase

HDAC6: 

Histone deacetylase 6

NFTs: 

Neurofibrillary tangles

Declarations

Acknowledgements

This work is partly supported by NIH grant NS083385 (to X.Z.) and by Alzheimer Association grant IIRG-13-284849 (to GP), by Chinese Overseas, Hong Kong and Macao Scholars Collaborated Research Fund Grant 81228007 to X. Z. and by the Dr. Robert M. Kohrman Memorial Fund.

Authors’ Affiliations

(1)
Department of Pathology, Case Western Reserve University
(2)
Department of Neurosurgery, Shandong Provincial Hospital, Shandong University
(3)
Department of Neurobiology, Shandong University
(4)
Department of Neurology, the Second Xiangya Hospital, Central South University
(5)
Departamento de Neurobiología del Desarrollo y Neurofisiología, Instituto de Neurobiología, Universidad Nacional Autónoma de México Querétaro
(6)
The University of Texas at San Antonio, One UTSA Circle
(7)

References

  1. Wang JZ, Xia YY, Grundke-Iqbal I, Iqbal K. Abnormal hyperphosphorylation of tau: sites, regulation, and molecular mechanism of neurofibrillary degeneration. J Alzheimers Dis. 2013;33 Suppl 1:S123–39. doi:10.3233/JAD-2012-129031.PubMedGoogle Scholar
  2. Iqbal K, Gong CX, Liu F. Microtubule-associated protein tau as a therapeutic target in Alzheimer's disease. Expert Opin Ther Targets. 2014;18(3):307–18. doi:10.1517/14728222.2014.870156.View ArticlePubMedGoogle Scholar
  3. Iqbal K, Liu F, Gong CX, Alonso Adel C, Grundke-Iqbal I. Mechanisms of tau-induced neurodegeneration. Acta Neuropathol. 2009;118(1):53–69. doi:10.1007/s00401-009-0486-3.View ArticlePubMed CentralPubMedGoogle Scholar
  4. Cash AD, Aliev G, Siedlak SL, Nunomura A, Fujioka H, Zhu X, et al. Microtubule reduction in Alzheimer's disease and aging is independent of tau filament formation. Am J Pathol. 2003;162(5):1623–7.View ArticlePubMed CentralPubMedGoogle Scholar
  5. Scheff SW, DeKosky ST, Price DA. Quantitative assessment of cortical synaptic density in Alzheimer's disease. Neurobiol Aging. 1990;11(1):29–37.View ArticlePubMedGoogle Scholar
  6. Praprotnik D, Smith MA, Richey PL, Vinters HV, Perry G. Filament heterogeneity within the dystrophic neurites of senile plaques suggests blockage of fast axonal transport in Alzheimer's disease. Acta Neuropathol. 1996;91(3):226–35.View ArticlePubMedGoogle Scholar
  7. Terry RD. The pathogenesis of Alzheimer disease: an alternative to the amyloid hypothesis. J Neuropathol Exp Neurol. 1996;55(10):1023–5.View ArticlePubMedGoogle Scholar
  8. Hirai K, Aliev G, Nunomura A, Fujioka H, Russell RL, Atwood CS, et al. Mitochondrial abnormalities in Alzheimer's disease. J Neurosci. 2001;21(9):3017–23.PubMedGoogle Scholar
  9. Morsch R, Simon W, Coleman PD. Neurons may live for decades with neurofibrillary tangles. J Neuropathol Exp Neurol. 1999;58(2):188–97.View ArticlePubMedGoogle Scholar
  10. Kuchibhotla KV, Wegmann S, Kopeikina KJ, Hawkes J, Rudinskiy N, Andermann ML, et al. Neurofibrillary tangle-bearing neurons are functionally integrated in cortical circuits in vivo. Proc Natl Acad Sci U S A. 2014;111(1):510–4. doi:10.1073/pnas.1318807111.View ArticlePubMed CentralPubMedGoogle Scholar
  11. Fukushima N, Furuta D, Hidaka Y, Moriyama R, Tsujiuchi T. Post-translational modifications of tubulin in the nervous system. J Neurochem. 2009;109(3):683–93. doi:10.1111/j.1471-4159.2009.06013.x.View ArticlePubMedGoogle Scholar
  12. Song Y, Brady ST. Post-translational modifications of tubulin: pathways to functional diversity of microtubules. Trends Cell Biol. 2014. doi:10.1016/j.tcb.2014.10.004.
  13. Zhu X, Rottkamp CA, Boux H, Takeda A, Perry G, Smith MA. Activation of p38 kinase links tau phosphorylation, oxidative stress, and cell cycle-related events in Alzheimer disease. J Neuropathol Exp Neurol. 2000;59(10):880–8.PubMedGoogle Scholar
  14. Hempen B, Brion JP. Reduction of acetylated alpha-tubulin immunoreactivity in neurofibrillary tangle-bearing neurons in Alzheimer's disease. J Neuropathol Exp Neurol. 1996;55(9):964–72.View ArticlePubMedGoogle Scholar
  15. Gray EG, Paula-Barbosa M, Roher A. Alzheimer's disease: paired helical filaments and cytomembranes. Neuropathol Appl Neurobiol. 1987;13(2):91–110.View ArticlePubMedGoogle Scholar
  16. Smith MA, Casadesus G, Joseph JA, Perry G. Amyloid-beta and tau serve antioxidant functions in the aging and Alzheimer brain. Free Radic Biol Med. 2002;33(9):1194–9.View ArticlePubMedGoogle Scholar
  17. Wang X, Perry G, Smith MA, Zhu X. Amyloid-beta-derived diffusible ligands cause impaired axonal transport of mitochondria in neurons. Neuro-degenerative diseases. 2010;7(1–3):56–9. doi:10.1159/000283484.View ArticlePubMed CentralPubMedGoogle Scholar
  18. Stokin GB, Lillo C, Falzone TL, Brusch RG, Rockenstein E, Mount SL, et al. Axonopathy and transport deficits early in the pathogenesis of Alzheimer's disease. Science. 2005;307(5713):1282–8.View ArticlePubMedGoogle Scholar
  19. Zhu X, Moreira PI, Smith MA, Perry G. Alzheimer's disease: an intracellular movement disorder? Trends Mol Med. 2005;11(9):391–3. doi:10.1016/j.molmed.2005.07.002.View ArticlePubMedGoogle Scholar
  20. Wang X, Su B, Lee HG, Li X, Perry G, Smith MA, et al. Impaired balance of mitochondrial fission and fusion in Alzheimer's disease. J Neurosci. 2009;29(28):9090–103. doi:10.1523/JNEUROSCI.1357-09.2009.View ArticlePubMed CentralPubMedGoogle Scholar
  21. L'Hernault SW, Rosenbaum JL. Chlamydomonas alpha-tubulin is posttranslationally modified by acetylation on the epsilon-amino group of a lysine. Biochemistry. 1985;24(2):473–8.View ArticlePubMedGoogle Scholar
  22. LeDizet M, Piperno G. Identification of an acetylation site of Chlamydomonas alpha-tubulin. Proc Natl Acad Sci U S A. 1987;84(16):5720–4.View ArticlePubMed CentralPubMedGoogle Scholar
  23. Kull FJ, Sloboda RD. A slow dance for microtubule acetylation. Cell. 2014;157(6):1255–6. doi:10.1016/j.cell.2014.05.021.View ArticlePubMedGoogle Scholar
  24. Janke C, Kneussel M. Tubulin post-translational modifications: encoding functions on the neuronal microtubule cytoskeleton. Trends Neurosci. 2010;33(8):362–72. doi:10.1016/j.tins.2010.05.001.View ArticlePubMedGoogle Scholar
  25. Hubbert C, Guardiola A, Shao R, Kawaguchi Y, Ito A, Nixon A, et al. HDAC6 is a microtubule-associated deacetylase. Nature. 2002;417(6887):455–8. doi:10.1038/417455a 417455a.View ArticlePubMedGoogle Scholar
  26. Cueva JG, Hsin J, Huang KC, Goodman MB. Posttranslational acetylation of alpha-tubulin constrains protofilament number in native microtubules. Curr Biol. 2012;22(12):1066–74. doi:10.1016/j.cub.2012.05.012.View ArticlePubMed CentralPubMedGoogle Scholar
  27. Sharp DJ, Ross JL. Microtubule-severing enzymes at the cutting edge. J Cell Sci. 2012;125(Pt 11):2561–9. doi:10.1242/jcs.101139.View ArticlePubMed CentralPubMedGoogle Scholar
  28. Bhuwania R, Castro-Castro A, Linder S. Microtubule acetylation regulates dynamics of KIF1C-powered vesicles and contact of microtubule plus ends with podosomes. Eur J Cell Biol. 2014;93(10–12):424–37. doi:10.1016/j.ejcb.2014.07.006.View ArticlePubMedGoogle Scholar
  29. Reed NA, Cai D, Blasius TL, Jih GT, Meyhofer E, Gaertig J, et al. Microtubule acetylation promotes kinesin-1 binding and transport. Curr Biol. 2006;16(21):2166–72. doi:10.1016/j.cub.2006.09.014.View ArticlePubMedGoogle Scholar
  30. Bulinski JC. Microtubule modification: acetylation speeds anterograde traffic flow. Curr Biol. 2007;17(1):R18–20. doi:10.1016/j.cub.2006.11.036.View ArticlePubMedGoogle Scholar
  31. Kaul N, Soppina V, Verhey KJ. Effects of alpha-tubulin K40 acetylation and detyrosination on kinesin-1 motility in a purified system. Biophys J. 2014;106(12):2636–43. doi:10.1016/j.bpj.2014.05.008.View ArticlePubMedGoogle Scholar
  32. Walter WJ, Beranek V, Fischermeier E, Diez S. Tubulin acetylation alone does not affect kinesin-1 velocity and run length in vitro. PLoS ONE. 2012;7(8):e42218. doi:10.1371/journal.pone.0042218.View ArticlePubMed CentralPubMedGoogle Scholar
  33. Bianchi M, Heidbreder C, Crespi F. Cytoskeletal changes in the hippocampus following restraint stress: role of serotonin and microtubules. Synapse. 2003;49(3):188–94. doi:10.1002/syn.10230.View ArticlePubMedGoogle Scholar
  34. Mackeh R, Lorin S, Ratier A, Mejdoubi-Charef N, Baillet A, Bruneel A, et al. Reactive oxygen species, AMP-activated protein kinase, and the transcription cofactor p300 regulate alpha-tubulin acetyltransferase-1 (alphaTAT-1/MEC-17)-dependent microtubule hyperacetylation during cell stress. J Biol Chem. 2014;289(17):11816–28. doi:10.1074/jbc.M113.507400.View ArticlePubMed CentralPubMedGoogle Scholar
  35. McLendon PM, Ferguson BS, Osinska H, Bhuiyan MS, James J, McKinsey TA, et al. Tubulin hyperacetylation is adaptive in cardiac proteotoxicity by promoting autophagy. Proc Natl Acad Sci U S A. 2014;111(48):E5178–86. doi:10.1073/pnas.1415589111.View ArticlePubMedGoogle Scholar
  36. Giustiniani J, Daire V, Cantaloube I, Durand G, Pous C, Perdiz D, et al. Tubulin acetylation favors Hsp90 recruitment to microtubules and stimulates the signaling function of the Hsp90 clients Akt/PKB and p53. Cell Signal. 2009;21(4):529–39. doi:10.1016/j.cellsig.2008.12.004.View ArticlePubMedGoogle Scholar
  37. Dompierre JP, Godin JD, Charrin BC, Cordelieres FP, King SJ, Humbert S, et al. Histone deacetylase 6 inhibition compensates for the transport deficit in Huntington's disease by increasing tubulin acetylation. J Neurosci. 2007;27(13):3571–83. doi:10.1523/JNEUROSCI.0037-07.2007.View ArticlePubMedGoogle Scholar
  38. Xiong Y, Zhao K, Wu J, Xu Z, Jin S, Zhang YQ. HDAC6 mutations rescue human tau-induced microtubule defects in Drosophila. Proc Natl Acad Sci U S A. 2013;110(12):4604–9. doi:10.1073/pnas.1207586110.View ArticlePubMed CentralPubMedGoogle Scholar
  39. Kilgore M, Miller CA, Fass DM, Hennig KM, Haggarty SJ, Sweatt JD, et al. Inhibitors of class 1 histone deacetylases reverse contextual memory deficits in a mouse model of Alzheimer's disease. Neuropsychopharmacology. 2010;35(4):870–80. doi:10.1038/npp.2009.197.View ArticlePubMed CentralPubMedGoogle Scholar
  40. Govindarajan N, Rao P, Burkhardt S, Sananbenesi F, Schluter OM, Bradke F, et al. Reducing HDAC6 ameliorates cognitive deficits in a mouse model for Alzheimer's disease. EMBO Mol Med. 2013;5(1):52–63. doi:10.1002/emmm.201201923.View ArticlePubMed CentralPubMedGoogle Scholar
  41. Selenica ML, Benner L, Housley SB, Manchec B, Lee DC, Nash KR, et al. Histone deacetylase 6 inhibition improves memory and reduces total tau levels in a mouse model of tau deposition. Alzheimers Res Ther. 2014;6(1):12. doi:10.1186/alzrt241.View ArticlePubMed CentralPubMedGoogle Scholar
  42. Edde B, Rossier J, Le Caer JP, Desbruyeres E, Gros F, Denoulet P. Posttranslational glutamylation of alpha-tubulin. Science. 1990;247(4938):83–5.View ArticlePubMedGoogle Scholar
  43. Alexander JE, Hunt DF, Lee MK, Shabanowitz J, Michel H, Berlin SC, et al. Characterization of posttranslational modifications in neuron-specific class III beta-tubulin by mass spectrometry. Proc Natl Acad Sci U S A. 1991;88(11):4685–9.View ArticlePubMed CentralPubMedGoogle Scholar
  44. Redeker V, Melki R, Prome D, Le Caer JP, Rossier J. Structure of tubulin C-terminal domain obtained by subtilisin treatment. The major alpha and beta tubulin isotypes from pig brain are glutamylated. FEBS Lett. 1992;313(2):185–92. doi:0014-5793(92)81441-N.View ArticlePubMedGoogle Scholar
  45. Gagnon C, White D, Cosson J, Huitorel P, Edde B, Desbruyeres E, et al. The polyglutamylated lateral chain of alpha-tubulin plays a key role in flagellar motility. J Cell Sci. 1996;109(Pt 6):1545–53.PubMedGoogle Scholar
  46. van Dijk J, Rogowski K, Miro J, Lacroix B, Edde B, Janke C. A targeted multienzyme mechanism for selective microtubule polyglutamylation. Mol Cell. 2007;26(3):437–48. doi:10.1016/j.molcel.2007.04.012.View ArticlePubMedGoogle Scholar
  47. Janke C, Rogowski K, van Dijk J. Polyglutamylation: a fine-regulator of protein function? 'Protein Modifications: beyond the usual suspects' review series. EMBO Rep. 2008;9(7):636–41. doi:10.1038/embor.2008.114.View ArticlePubMed CentralPubMedGoogle Scholar
  48. Boucher D, Larcher JC, Gros F, Denoulet P. Polyglutamylation of tubulin as a progressive regulator of in vitro interactions between the microtubule-associated protein Tau and tubulin. Biochemistry. 1994;33(41):12471–7.View ArticlePubMedGoogle Scholar
  49. Larcher JC, Boucher D, Lazereg S, Gros F, Denoulet P. Interaction of kinesin motor domains with alpha- and beta-tubulin subunits at a tau-independent binding site. Regulation by polyglutamylation. J Biol Chem. 1996;271(36):22117–24.View ArticlePubMedGoogle Scholar
  50. Bonnet C, Boucher D, Lazereg S, Pedrotti B, Islam K, Denoulet P, et al. Differential binding regulation of microtubule-associated proteins MAP1A, MAP1B, and MAP2 by tubulin polyglutamylation. J Biol Chem. 2001;276(16):12839–48. doi:10.1074/jbc.M011380200.View ArticlePubMedGoogle Scholar
  51. Ikegami K, Heier RL, Taruishi M, Takagi H, Mukai M, Shimma S, et al. Loss of alpha-tubulin polyglutamylation in ROSA22 mice is associated with abnormal targeting of KIF1A and modulated synaptic function. Proc Natl Acad Sci U S A. 2007;104(9):3213–8. doi:0611547104 [pii] 10.1073/pnas.0611547104.View ArticlePubMed CentralPubMedGoogle Scholar
  52. Sirajuddin M, Rice LM, Vale RD. Regulation of microtubule motors by tubulin isotypes and post-translational modifications. Nature cell biology. 2014;16(4):335–44. doi:10.1038/ncb2920.View ArticlePubMed CentralPubMedGoogle Scholar
  53. Lacroix B, van Dijk J, Gold ND, Guizetti J, Aldrian-Herrada G, Rogowski K, et al. Tubulin polyglutamylation stimulates spastin-mediated microtubule severing. J Cell Biol. 2010;189(6):945–54. doi:10.1083/jcb.201001024.View ArticlePubMed CentralPubMedGoogle Scholar
  54. Wloga D, Dave D, Meagley J, Rogowski K, Jerka-Dziadosz M, Gaertig J. Hyperglutamylation of tubulin can either stabilize or destabilize microtubules in the same cell. Eukaryotic cell. 2010;9(1):184–93. doi:10.1128/EC.00176-09.View ArticlePubMed CentralPubMedGoogle Scholar

Copyright

© Zhang et al.; licensee BioMed Central. 2015

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Advertisement